Plaqenil Role in Prevention of Age Related Macular Degeneration

The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2012 by Ziv Hospital.
Recruitment status was  Recruiting
Sponsor:
Information provided by (Responsible Party):
Ziv Hospital
ClinicalTrials.gov Identifier:
NCT01541449
First received: February 2, 2012
Last updated: February 29, 2012
Last verified: January 2012
  Purpose

The investigators think that there is a connection between the use of plaquenil and the prevention of Age related macular degeneration (AMD). The investigators believe that the use of plaquenil makes bruch's membrane thicker, thereby preventing Chroidal Neovascularization (CNV) growth.


Condition
Age Related Macular Degeneration

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Retrospective
Official Title: Observational Study Between People That Use Plaquenil and Those Who do Not in Prevention of AMD.

Resource links provided by NLM:


Further study details as provided by Ziv Hospital:

Estimated Enrollment: 30
Study Start Date: January 2012
Estimated Study Completion Date: April 2012
Groups/Cohorts
RA patients treated with plaquenil
Patients who do not use plaquenil

Detailed Description:

the study is done by comparing to groups RA patients who take plaquenil Vs. group of patients who do not take plaquenil. after measuring the retina thickness we compare the avg. thickness of both groups.

  Eligibility

Ages Eligible for Study:   20 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Ziv Medical center retina clinic population

Criteria

Inclusion Criteria:

  • all people who suffer from rheumatoid arthritis (RA) and use plaquenil

Exclusion Criteria:

  • patients who did not complete follow-up
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01541449

Contacts
Contact: Joseph Pikkel, M.D 0508434206 pikel.y@ziv.health.gov.il

Locations
Israel
Ziv Medical Center Recruiting
Safed, Israel, 13100
Contact: Otzem Chassid, M.D    0506266059    otzem@yahoo.com   
Sponsors and Collaborators
Ziv Hospital
Investigators
Principal Investigator: Joseph pikkel, M.D Ziv Medical Center
  More Information

No publications provided

Responsible Party: Ziv Hospital
ClinicalTrials.gov Identifier: NCT01541449     History of Changes
Other Study ID Numbers: ZIV-0061-11
Study First Received: February 2, 2012
Last Updated: February 29, 2012
Health Authority: Israel: Ethics Commission

Keywords provided by Ziv Hospital:
AMD
PLAQUENIL
CNV

Additional relevant MeSH terms:
Macular Degeneration
Retinal Degeneration
Retinal Diseases
Eye Diseases
Hydroxychloroquine
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Antirheumatic Agents
Therapeutic Uses
Antimalarials
Antiprotozoal Agents
Antiparasitic Agents
Anti-Infective Agents

ClinicalTrials.gov processed this record on April 21, 2014